Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma

ASH 2024

7 - 10 Dec 2024

Published: 17 Dec 2024

Views: 13

Rating:

Save

Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA

Dr Christina Poh speaks to ecancer about the inMIND study presented at ASH 2024.

This phase three trial evaluated the effectiveness of adding tafasitamab to rituximab with lenalidomide in patients with relapse or refractory follicular lymphoma.

She reports that the study showed a significant improvement in progression-free survival, with 22.4 months for the tafasitamab group versus 13.9 months for the control group.

This combination therapy may reshape treatment strategies for follicular lymphoma, with manageable safety profiles.

Related Videos

Impact of MRD on progression-free survival in MM patients treated with...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

Daratumumab-based maintenance regimens show favourable responses in ransplant...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Daratumumab-based maintenance regimens show favourable responses in ransplant-eligible NDMM ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Approaches to risk stratification in high risk myeloma

Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA

Approaches to risk stratification in high risk myeloma ( Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA )

Tailored to fit: New approaches in transplant-ineligible NDMM

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Tailored to fit: New approaches in transplant-ineligible NDMM ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Advancements in minimal residual disease detection in myeloma

Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada

Advancements in minimal residual disease detection in myeloma ( Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

More from ecancer